- Trial phase
- Phase 3 (completed, failed primary endpoint)
- Time to market
- Unknown, the Phase 3 trial failed its primary endpoint, and no regulatory submission path has been determined. The drug may be years away or may never reach market.
- Why 3/10
- No upcoming binary catalyst is scheduled, the Phase 3 HARBOR trial has already failed its primary endpoint (September 8, 2026), and Novartis has not committed to a regulatory filing. For a large-cap pharma like NVS (~$200B+ market cap), del-desiran is one of many pipeline assets, so even a complete program termination would be a modest incremental headwind rather than a company-defining event.
The Phase 3 HARBOR trial has already failed, and no regulatory submission or next pivotal readout is scheduled. Watch for Novartis's full data presentation at a medical conference and any decision on whether to pursue a regulatory path based on secondary endpoints, either outcome would be incremental for a stock with a $200B+ market cap and dozens of marketed products.
Price Chart
Executive Summary
Del-desiran (delpacibart etedesiran, formerly AOC 1001) is an antibody-oligonucleotide conjugate developed by Novartis (NVS) for myotonic dystrophy type 1 (DM1), a rare progressive muscle-wasting disease with no approved treatments. The drug was the lead asset from Novartis's ~$12B acquisition of Avidity Biosciences. On September 8, 2026, Novartis announced that the global Phase 3 HARBOR trial failed to meet its primary endpoint (video hand opening time), sending NVS shares down ~14% in a single day. While Novartis reported "evidence of clinical activity" in secondary endpoints, the company has not committed to a regulatory path and is still analyzing the full dataset. For a large-cap pharma like Novartis, this is a meaningful pipeline setback but not a company-threatening event.
How It Works
Del-desiran is an antibody-oligonucleotide conjugate, a synthetic molecule that combines a targeting antibody with a short piece of genetic material (siRNA). The antibody portion binds to a receptor (TfR1) found on muscle cells, which pulls the drug inside those cells. Once inside, the siRNA component triggers the cell's natural machinery to degrade the toxic DMPK RNA that causes myotonic dystrophy type 1, aiming to address the root cause of the disease.
Trial Status
The global Phase 3 HARBOR trial (NCT06411288) enrolled 159 patients with DM1 and randomized them to del-desiran or placebo every 8 weeks for 7 doses. The trial completed in July 2026. Topline results announced September 8, 2026 showed the drug did not meet its primary endpoint (video hand opening time, vHOT) with statistical significance. Novartis reported "evidence of clinical activity" in secondary and exploratory endpoints but has not disclosed detailed data. The company is analyzing the full dataset and plans to discuss next steps with health authorities.
The Two-Sided Case
Upcoming Catalysts
- Full HARBOR dataset presentation at a future medical conference (date TBD)
- Regulatory discussions with FDA and other health authorities on potential path forward
- Novartis decision on whether to continue development or terminate the program
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVARTIS AG 6-K NVS ·Originating report